Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: A post hoc analysis of data from a prospective, randomized, double-blind study

Clinical Drug Investigation

Volumn 30, Issue 7, 2010, Pages 453-460

  Walter, Thomas ^a   Szabo, Sebastian ^b   Suselbeck, Tim ^a   Borggrefe, Martin ^a   Lang, Siegfried ^a   Swoboda, Stefanie ^c   Hoffmeister, Hans Martin ^b   Dempfle, Carl Erik ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Staedtisches Klinikum   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Atorvastatin; Coronary artery disease; Fibrinolysis; Haemostasis; HMG CoA reductase inhibitors; Inflammation; Therapeutic use

Indexed keywords

ATORVASTATIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING INHIBITOR; C REACTIVE PROTEIN; CHOLESTEROL; D DIMER; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; SELECTIN; THROMBIN ANTITHROMBIN COMPLEX; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFLAMMATION; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

AGED; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBIN;

EID: 77953327552     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11536270-000000000-00000     Document Type: Article

References (33)

1. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 2007; 153 (5): 881-888
2. Seljeflot I, Tonstad S, Hjermann I, et al. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 2002; 162 (1): 179-185
3. Tousoulis D, Bosinakou E, Kotsopoulou M, et al. Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. Int J Cardiol 2006; 106 (3): 333-337
4. Seljeflot I, Tonstad S, Hjermann I, et al. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 2002; 105 (4): 285-290
5. Lopez S, Peiretti F, Bonardo B, et al. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 2000; 152 (2): 359-366
6. Wiesbauer F, Kaun C, Zorn G, et al. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 2002; 135 (1): 284-292
7. Kushiya F, Wada H, Ooi K, et al. Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis. Am J Hematol 2005; 78 (1): 1-6
8. Trifiletti A, Lasco A, Scamardi R, et al. Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin. Pathophysiol Haemost Thromb 2003; 33 (2): 84-87
9. Van De Ree MA, De Maat MP, Kluft C, et al. Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with type 2 diabetes mellitus. J Thromb Haemost 2003; 1 (8): 1753-1757
10. Bruni F, Pasqui AL, Pastorelli M, et al. Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects. Int J Cardiol 2004; 95 (2-3): 269-274
11. Sakata K, Hoshino T, Yoshida H, et al. Circadian fluctuations of tissue plasminogen activator antigen and plasminogen activator inhibitor-1 antigens in vasospastic angina. Am Heart J 1992; 124: 854-860
12. Brown NJ, Agirbasli MA, Williams GH, et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32 (6): 965-971
13. Garcia Frade LJ, Alvarez JJ, Rayo I, et al. Fibrinolytic parameters and lipoprotein (a) levels in plasma of patients with coronary artery disease. Thromb Res 1991; 63: 407-418
14. Hoffmeister HM, Jur M, Wendel HP, et al. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995; 91: 2520-2527
15. Murakami T, Komiyama Y,Masuda M, et al. Evaluation of factor XIa-alpha 1-antitrypsin in plasma, a contact phaseactivated coagulation factor-inhibitor complex, in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 1995; 15: 1107-1113
16. The ECAT Study Group. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17
17. Tekin A, Tekin G, Guzelsoy D, et al. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. Am J Cardiol 2004; 94 (2): 206-209
18. Mosesson MW, Siebenlist KR, Hernandez I, et al. Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation. J Thromb Haemost 2008; 6 (9): 1565-1570
19. Son JW, Koh KK, Ahn JY, et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003; 88 (1): 77-82
20. Ushiroyama T, Nosaka S, Ueki M. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women. Int J Cardiol 2006; 113 (1): 66-75
21. Hackman A, Abe Y, Insull Jr W, et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996; 93 (7): 1334-1338
22. Ozaki K, Kubo T, Imaki R, et al. The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia. J Atheroscler Thromb 2006; 13 (4): 216-219
23. Alber HF, Frick M, Sussenbacher A, et al. Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease. Wien MedWochenschr 2007; 157 (3-4): 73-78
24. Puccetti L, Sawamura T, Pasqui AL, et al. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients. Eur J Clin Invest 2005; 35 (1): 47-51
25. Bruni F, Pasqui AL, Pastorelli M, et al. Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects. Clin Appl Thromb Hemost 2005; 11 (4): 417-428
26. Puccetti L, Pasqui AL, Pastorelli M, et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002; 32 (12): 901-908
27. Puccetti L, Pasqui AL, Pastorelli M, et al. 30UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects. Atherosclerosis 2005; 183 (2): 322-328
28. Puccetti L, Bruni F, Pasqui AL, et al. Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia. Eur J Clin Invest 2008; 38 (1): 11-16
29. Lam HC, Chu CH, Wei MC, et al. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia. Exp Biol Med (Maywood) 2006; 231 (6): 1010-1015
30. Ray KK, Cannon CP, Cairns R, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46 (8): 1417-1424
31. Tousoulis D, Antoniades C, Katsi V, et al. The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. Int J Cardiol 2006; 109 (1): 48-52
32. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24 (1): 33-50
33. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol 2005; 96 (5A): 54F-60F